Ipsen files new Decapeptyl formulation in Europe
This article was originally published in Scrip
Ipsen has filed its six-month sustained-release formulation of Decapeptyl (triptorelin pamoate) in Europe for the treatment of locally advanced or metastastic hormone-dependent prostate cancer.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.